Bottom line
Is DNUP a good fund? The bottom line
DNUP is a managed leveraged & inverse ETF from SEI.
Its expense ratio is 1.5% — about $150 a year on every $10,000 invested, more expensive than 83% of leveraged & inverse funds we track.
What to watch
- Expensive for its category (1.5%)
Updated Nov 19, 2026
What DNUP invests in
The Fund seeks daily investment results, before fees and expenses, of 200% of the daily performance of DNA. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day.
The Fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in financial instruments that are designed to provide, in the aggregate, 200% exposure to the price performance of DNA on a daily basis. The Fund may also seek to achieve its investment objective by purchasing call options on DNA or by investing directly in the common stock of DNA. The Adviser will determine the allocation of the Funds investments in swap agreements, call options and direct investments in DNA common stock based upon various factors including, but not limited to, counterparty capacity, financing charges, liquidity, collateral availability, and overall market conditions for a particular instrument. Direct investments in common stock of DNA are typically less efficient than the use of swap agreements because direct investments in common stock do not…
From the fund's prospectus (filed Apr 30, 2026).
What DNUP costs
On a $10,000 investment, DNUP's 1.5% expense ratio costs about $150 a year. The median leveraged & inverse fund charges 1.31%.